Ken Griffin
LFCR icon

Ken Griffin’s Lifecore Biomedical LFCR Stock Holding History

Ken Griffin’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$159K Sell
42,700
-26,500
-38% -$183K ﹤0.01% 11635
2025
Q4 		$566K Buy
+69,200
New +$512K ﹤0.01% 8723
2025
Q2 		– Sell
-1,400
Closed -$9.86K – 13939
2025
Q1 		$9.86K Buy
+1,400
New +$8.7K ﹤0.01% 13572
2024
Q3 		– Sell
-4,200
Closed -$21.5K – 14795
2024
Q2 		$21.5K Sell
4,200
-25,600
-86% -$152K ﹤0.01% 12567
2024
Q1 		$158K Buy
+29,800
New +$213K ﹤0.01% 10683
2023
Q4 		– Sell
-34,000
Closed -$257K – 14829
2023
Q3 		$257K Sell
34,000
-8,200
-19% -$75K ﹤0.01% 9450
2023
Q2 		$408K Buy
42,200
+16,700
+65% +$102K ﹤0.01% 8374
2023
Q1 		$96.3K Buy
25,500
+22,300
+697% +$124K ﹤0.01% 11323
2022
Q4 		$20.7K Buy
+3,200
New +$26.4K ﹤0.01% 13120
2022
Q2 		– Sell
-11,100
Closed -$129K – 13562
2022
Q1 		$129K Buy
+11,100
New +$124K ﹤0.01% 12020

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ken Griffin's LFCR Position: Q1 2026 in Review

Ken Griffin sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 18,116 shares — an estimated $125K sold.

Ken Griffin first reported a position in LFCR in Q3 2013 and held it in 28 quarters. The position peaked at $695K in Q1 2014. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • Ken Griffin reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 18,116 Lifecore Biomedical shares in Q1 2026, an estimated $125K.
  • Ken Griffin first reported a position in Lifecore Biomedical in Q3 2013 and held it in 28 quarters.
  • Ken Griffin's Lifecore Biomedical position peaked at $695K in Q1 2014.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.